Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Jul
31
2014
USPTO TRIPs Over Myriad-Mayo Guidance - Trade-related Aspects of Intellectual Property Rights Schwegman, Lundberg & Woessner, P.A.
Apr
4
2019
Cleveland Clinic II – Why Can’t a Diagnostic Conclusion be a Practical Application of a Natural Law? Schwegman, Lundberg & Woessner, P.A.
Dec
18
2014
Mayo Meet Alice Meet Myriad – Fed. Cir. Appreciates “Abstract Art” Schwegman, Lundberg & Woessner, P.A.
Jun
22
2015
Teva v. Sandoz – “Strange Brew” Boils Over Schwegman, Lundberg & Woessner, P.A.
Sep
4
2015
Sandoz Launches First Biosimilar Drug in U.S. Schwegman, Lundberg & Woessner, P.A.
Apr
26
2020
Chinese Rail System for Restaurant Meal Delivery Patent Infringed Schwegman, Lundberg & Woessner, P.A.
Jul
19
2017
Millennium Pharm. v. Sandoz, Inc. – Revenge of the Chemical Judges Schwegman, Lundberg & Woessner, P.A.
Sep
5
2017
Should the Australian Patent Office be denying patent eligibility to cDNA inventions? Schwegman, Lundberg & Woessner, P.A.
Mar
9
2013
UK National Stem Cell Network Report – The Patent Watch Landscape Schwegman, Lundberg & Woessner, P.A.
May
16
2013
CLS Bank v. Alice Corp. (Part 2) Re: Patent Litigation Schwegman, Lundberg & Woessner, P.A.
Jun
11
2018
PTO Issues Section 101 Memorandum after Vanda Decision Schwegman, Lundberg & Woessner, P.A.
May
9
2014
Dolly Led to Slaughter – Part II - Adult Cell Cloning Schwegman, Lundberg & Woessner, P.A.
Nov
3
2014
Canadian Hospital To Travel The Long And Winding Road Of “Gene Patenting” Schwegman, Lundberg & Woessner, P.A.
Dec
3
2015
Ariosa v. Sequenom – Cert. Denied Schwegman, Lundberg & Woessner, P.A.
Jan
29
2016
Labeling GMO’s — Too Late and Too Much Schwegman, Lundberg & Woessner, P.A.
Jun
16
2016
Patent Prosecution: “Unclean Hands” Doctrine Erases Merck’s Damage Award Schwegman, Lundberg & Woessner, P.A.
Jan
11
2024
Federal March-In Rights Meet Clawbacks – The Future of 35 USC ss. 200-212 Schwegman, Lundberg & Woessner, P.A.
Apr
1
2011
Banning Stem Cell Research — Or Cloning? Or Both? Schwegman, Lundberg & Woessner, P.A.
Feb
5
2013
Time For Myriad To Fight Another Day - DNA Composition Schwegman, Lundberg & Woessner, P.A.
Jun
4
2018
Ex Parte Galloway – Berkheimer Meet s. 103 Schwegman, Lundberg & Woessner, P.A.
Oct
3
2013
Skinmedica, Inc. and, i.e., Disclaimer Re: Patent Litigation Schwegman, Lundberg & Woessner, P.A.
Jun
19
2014
Alice v. CLS Bank: Supreme Court Continues to Grope in Dark for Contours of Abstract Idea Exception Schwegman, Lundberg & Woessner, P.A.
Jul
7
2014
Abbvie V. Janssen Biotech –Written Description Requirement Road Map Schwegman, Lundberg & Woessner, P.A.
Sep
5
2014
Australia: Cancer Voices v Myriad Opinion Affirmed Schwegman, Lundberg & Woessner, P.A.
Jan
20
2015
Promega v. Life Technologies – “Too Much Of Nothing?” re: Patent Infringement Schwegman, Lundberg & Woessner, P.A.
Oct
7
2023
The Tyranny of Large Numbers: Their Grip on s. 102 Inquiries Schwegman, Lundberg & Woessner, P.A.
Mar
30
2017
ABA-IPL Section Proposes Amendments to s. 101 – Too much of a “Good Thing”? Schwegman, Lundberg & Woessner, P.A.
Jan
11
2021
American Axle Petitions for Cert. Schwegman, Lundberg & Woessner, P.A.
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins